Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PBK | Q96KB5 | 2/20 | 0.53 |
| ▸ | AKT2 | P31751 | 1/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 7/20 | 0.44 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.41 |
| ▸ | JAK3 | P52333 | 3/20 | 0.39 |
| ▸ | JAK1 | P23458 | 3/20 | 0.39 |
| ▸ | JAK2 | O60674 | 2/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12613697 | 0.88 | PBK (0.52) | PBKAKT2NUDT1JAK3JAK1 | |
| SCHEMBL12612703 | 0.86 | PBK (0.44) | PBKNOTUMJAK3JAK1JAK2 | |
| SCHEMBL12613466 | 0.86 | PBK (0.50) | PBKAKT2JAK3JAK1JAK2 | |
| SCHEMBL12614108 | 0.85 | PBK (0.46) | PBKAKT2NUDT1JAK3JAK1 | |
| SCHEMBL12612734 | 0.85 | JAK3 (0.48) | AKT2JAK3JAK1JAK2DYRK1A | |
| SCHEMBL15421896 | 0.84 | AKT2 (0.48) | PBKAKT2NUDT1JAK3JAK1 | |
| SCHEMBL12612274 | 0.84 | AKT2 (0.48) | PBKAKT2NUDT1JAK3JAK1 | |
| SCHEMBL12613117 | 0.84 | JAK1 (0.54) | PBKJAK3JAK1JAK2TYK2 | |
| SCHEMBL19292290 | 0.84 | PBK (0.47) | PBKAKT2NUDT1JAK3JAK1 | |
| SCHEMBL12613878 | 0.84 | PBK (0.47) | PBKAKT2JAK3JAK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2688890-B1 | SUBSTITUTED FUSED TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADVINUS THERAPEUTICS LTD (IN) | 2017-08-30 | — | — | EP | claimed |
| US-9115133-B2 | Substituted fused tricyclic compounds, compositions and medicinal applications thereof | ADVINUS THERAPEUTICS LIMITED (US) | 2015-08-25 | — | — | US | claimed |
| EP-2688890-A1 | SUBSTITUTED FUSED TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | Advinus Therapeutics Limited (IN) | 2014-01-29 | — | — | EP | claimed |
| US-20140023614-A1 | SUBSTITUTED FUSED TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADVINUS THERAPEUTICS LTD. | 2014-01-23 | — | — | US | claimed |
| WO-2012127506-A1 | SUBSTITUTED FUSED TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADVINUS THERAPEUTICS LIMITED (IN) | 2012-09-27 | — | — | WO | claimed |
| EP-2688890-B1 | SUBSTITUTED FUSED TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADVINUS THERAPEUTICS LTD (IN) | 2017-08-30 | — | — | EP | disclosed |
| US-9115133-B2 | Substituted fused tricyclic compounds, compositions and medicinal applications thereof | ADVINUS THERAPEUTICS LIMITED (US) | 2015-08-25 | — | — | US | disclosed |
| EP-2688890-A1 | SUBSTITUTED FUSED TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | Advinus Therapeutics Limited (IN) | 2014-01-29 | — | — | EP | disclosed |
| US-20140023614-A1 | SUBSTITUTED FUSED TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADVINUS THERAPEUTICS LTD. | 2014-01-23 | — | — | US | disclosed |
| WO-2012127506-A1 | SUBSTITUTED FUSED TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADVINUS THERAPEUTICS LIMITED (IN) | 2012-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140023614-A1 | SUBSTITUTED FUSED TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | MALT1, JAK1, ICOS | PBK 16/4885AKT2 1913/4885NOTUM 3564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.